Autophagy dictates sensitivity to PRMT5 inhibitor in breast cancer

Protein arginine methyltransferase 5 (PRMT5) catalyzes mono-methylation and symmetric di-methylation on arginine residues and has emerged as a potential antitumor target with inhibitors being tested in clinical trials. However, it remains unknown how the efficacy of PRMT5 inhibitors is regulated. He...

Descripción completa

Detalles Bibliográficos
Autores principales: Brobbey, Charles, Yin, Shasha, Liu, Liu, Ball, Lauren E., Howe, Philip H., Delaney, Joe R., Gan, Wenjian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318021/
https://www.ncbi.nlm.nih.gov/pubmed/37400460
http://dx.doi.org/10.1038/s41598-023-37706-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318021/
https://www.ncbi.nlm.nih.gov/pubmed/37400460
http://dx.doi.org/10.1038/s41598-023-37706-9

Ejemplares similares